Leap Therapeutics Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Leap Therapeutics stock.
View analyst ratings for Leap Therapeutics or view top-rated stocks.

Wall Street analysts have given Leap Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Leap Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Leap Therapeutics.

Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings results on Friday, May, 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. Leap Therapeutics had a negative trailing twelve-month return on equity of 59.46% and a negative net margin of 1,961.13%.
View Leap Therapeutics' earnings history.

Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LPTX shares have decreased by 10.4% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19.

4 analysts have issued 12-month price objectives for Leap Therapeutics' stock. Their forecasts range from $3.50 to $8.00. On average, they anticipate Leap Therapeutics' share price to reach $4.88 in the next twelve months. This suggests a possible upside of 170.8% from the stock's current price.
View analysts' price targets for Leap Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Leap Therapeutics include Oramed Pharmaceuticals (ORMP), Verona Pharma (VRNA), Amryt Pharma (AMYT), Cue Biopharma (CUE), KemPharm (KMPH), Homology Medicines (FIXX), Kala Pharmaceuticals (KALA), Mawson Infrastructure Group (WIZP), VistaGen Therapeutics (VTGN), Angion Biomedica (ANGN), Nature's Sunshine Products (NATR), DURECT (DRRX), Inozyme Pharma (INZY), 89bio (ETNB) and NexImmune (NEXI).
View all of LPTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK), VYNE Therapeutics (VYNE), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL).

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Leap Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Hillhouse Capital Advisors LTD. (5.99%), Platinum Investment Management Ltd. (1.53%), Opaleye Management Inc. (0.65%), Geode Capital Management LLC (0.59%), Silverarc Capital Management LLC (0.50%) and BlackRock Inc. (0.36%).
View institutional ownership trends for Leap Therapeutics.

LPTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Platinum Investment Management Ltd., Hillhouse Capital Advisors LTD., Golden Green Inc., Acadian Asset Management LLC, McAdam LLC, Millennium Management LLC, and Clear Harbor Asset Management LLC.
View insider buying and selling activity for Leap Therapeutics or view top insider-selling stocks.

LPTX stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Geode Capital Management LLC, Morgan Stanley, Silverarc Capital Management LLC, Barclays PLC, Virtu Financial LLC, D.A. Davidson & CO., and BlackRock Inc..
View insider buying and selling activity for Leap Therapeutics or or view top insider-buying stocks.

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LPTX stock can currently be purchased for approximately $1.80.

Leap Therapeutics has a market capitalization of $107.41 million and generates $1.50 million in revenue each year. The company earns $-27,510,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

Leap Therapeutics employs 30 workers across the globe.

The official website for Leap Therapeutics is www.leaptx.com.

Leap Therapeutics is headquartered at 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141.

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360 or via email at [email protected]